GW’s cannabinoid-based Epidiolex scores another Phase III epilepsy victory


The company that nearly a year ago became the first to receive Food and Drug Administration approval for a cannabinoid-based drug has another positive Phase III trial under its belt. Cambridge, UK-based GW Pharmaceuticals said Monday that its Phase III trial of Epidiolex (cannabidiol) in patients aged 1 to 65 experiencing treatment-resistant seizures associated with tuberous sclerosis complex had met its primary endpoint. TSC is a rare and severe form of childhood-onset epilepsy.

Ga naar Bron